Login Register Cart 0
Research Article

洛哌丁胺诱导的便秘通过补体C3及其受体激活SD大鼠中结肠炎症信号通路

卷 22, 期 5, 2022

发表于: 24 August, 2021

页: [458 - 469] 页: 12

弟呕挨: 10.2174/1566524021666210618124220

open access plus

摘要

背景：补体成分3（C3）受体在先天免疫系统中作为炎症介质发挥着重要作用，尽管其在便秘中的作用机制尚未得到充分研究。 目的：本研究旨在探讨C3及其受体下游信号在便秘中的调节作用。 方法：测定洛哌丁胺（Lop）治疗的SD大鼠结肠中部C3、C3a受体（C3aR）和C3b受体（C3bR）表达、PI3K/AKT途径、RhoA/MLC途径、MAP激酶途径和炎性细胞因子表达的变化。 结果：Lop治疗成功诱导便秘表型，包括粪便参数下降和组织结构改变。在Lop诱导的便秘过程中，C3的表达水平显著升高，而C3aR和C3bR的表达降低。此外，Lop处理的SD大鼠结肠中部PI3K、AKT和GSK3β的磷酸化水平显著上调。Lop处理组中RhoA的表达和MLC的磷酸化也增强。此外，在MAP激酶途径和炎性细胞因子表达中也检测到类似的情况。经Lop治疗后，中结肠ERK和p38的磷酸化以及NF-κB、TNF-α、IL-6和IL-1α的mRNA水平显著升高。 结论：Lop诱导的便秘与SD大鼠中结肠C3aR和C3bR表达下调、C3和C3Rs下游信号通路上调密切相关，包括PI3K/AKT、RhoA/MLC、MAP激酶途径以及炎症细胞因子表达。

关键词: 补体C3、便秘、C3a受体、C3b受体、PI3K/AKT途径、洛哌丁胺

« Previous
[1]
Venkatesha RT, Berla Thangam E, Zaidi AK, Ali H. Distinct regulation of C3a-induced MCP-1/CCL2 and RANTES/CCL5 production in human mast cells by extracellular signal regulated kinase and PI3 kinase. Mol Immunol 2005; 42(5): 581-7.
[http://dx.doi.org/10.1016/j.molimm.2004.09.009] [PMID: 15607817]
[2]
Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med 2011; 17(3-4): 317-29.
[http://dx.doi.org/10.2119/molmed.2010.00149] [PMID: 21046060]
[3]
Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11(9): 785-97.
[http://dx.doi.org/10.1038/ni.1923] [PMID: 20720586]
[4]
Li K, Fazekasova H, Wang N, et al. Functional modulation of human monocytes derived DCs by anaphylatoxins C3a and C5a. Immunobiology 2012; 217(1): 65-73.
[http://dx.doi.org/10.1016/j.imbio.2011.07.033] [PMID: 21855168]
[5]
Dalmasso AP, Falk RJ, Raij L. The pathobiology of the terminal complement complexes. Complement Inflamm 1989; 6(1): 36-48.
[http://dx.doi.org/10.1159/000463070] [PMID: 2650989]
[6]
Reis ES, Mastellos DC, Hajishengallis G, Lambris JD. New insights into the immune functions of complement. Nat Rev Immunol 2019; 19(8): 503-16.
[http://dx.doi.org/10.1038/s41577-019-0168-x] [PMID: 31048789]
[7]
Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003; 17(9): 1003-14.
[http://dx.doi.org/10.1096/fj.02-0737com] [PMID: 12773483]
[8]
Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 2013; 190(8): 3839-47.
[http://dx.doi.org/10.4049/jimmunol.1203200] [PMID: 23564578]
[9]
Doepper S, Kacani L, Falkensammer B, Dierich MP, Stoiber H. Complement receptors in HIV infection. Curr Mol Med 2002; 2(8): 703-11.
[http://dx.doi.org/10.2174/1566524023361826] [PMID: 12462391]
[10]
Park JW, Kim JE, Choi YJ, et al. Deficiency of complement component 3 may be linked to the development of constipation in FVB/N-C3em1Hlee/Korl mice. FASEB J 2021; 35(1): e21221.
[http://dx.doi.org/10.1096/fj.202000376R] [PMID: 33337564]
[11]
Sugihara T, Kobori A, Imaeda H, et al. The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. Clin Exp Immunol 2010; 160(3): 386-93.
[http://dx.doi.org/10.1111/j.1365-2249.2010.04093.x] [PMID: 20089077]
[12]
Ahrenstedt O, Knutson L, Nilsson B, Nilsson-Ekdahl K, Odlind B, Hällgren R. Enhanced local production of complement components in the small intestines of patients with Crohn’s disease. N Engl J Med 1990; 322(19): 1345-9.
[http://dx.doi.org/10.1056/NEJM199005103221903] [PMID: 2325733]
[13]
Riordan SM, McIver CJ, Thomas MC, et al. The expression of complement protein 4 and IgG3 in luminal secretions. Scand J Gastroenterol 1996; 31(11): 1098-102.
[http://dx.doi.org/10.3109/00365529609036893] [PMID: 8938903]
[14]
Halstensen TS, Mollnes TE, Garred P, Fausa O, Brandtzaeg P. Surface epithelium related activation of complement differs in Crohn’s disease and ulcerative colitis. Gut 1992; 33(7): 902-8.
[http://dx.doi.org/10.1136/gut.33.7.902] [PMID: 1379568]
[15]
Ueki T, Mizuno M, Uesu T, et al. Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC). Clin Exp Immunol 1996; 104(2): 286-92.
[http://dx.doi.org/10.1046/j.1365-2249.1996.17721.x] [PMID: 8625522]
[16]
Lin F, Spencer D, Hatala DA, Levine AD, Medof ME. Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease. J Immunol 2004; 172(6): 3836-41.
[http://dx.doi.org/10.4049/jimmunol.172.6.3836] [PMID: 15004190]
[17]
Hughes S, Higgs NB, Turnberg LA. Loperamide has antisecretory activity in the human jejunum in vivo. Gut 1984; 25(9): 931-5.
[http://dx.doi.org/10.1136/gut.25.9.931] [PMID: 6590431]
[18]
Sohji Y, Kawashima K, Shimizu M. Pharmacological studies of loperamide, an anti-diarrheal agent. II. Effects on peristalsis of the small intestine and colon in guinea pigs (author’s transl) Nippon Yakurigaku Zasshi 1978; 74(1): 155-63.
[http://dx.doi.org/10.1254/fpj.74.155] [PMID: 640534]
[19]
Yamada K, Onoda Y. Comparison of the effects of T-1815, yohimbine and naloxone on mouse colonic propulsion. J Smooth Muscle Res 1993; 29(2): 47-53.
[http://dx.doi.org/10.1540/jsmr.29.47] [PMID: 8318729]
[20]
Lee HY, Kim JH, Jeung HW, et al. Effects of Ficus carica paste on loperamide-induced constipation in rats. Food Chem Toxicol 2012; 50(3-4): 895-902.
[http://dx.doi.org/10.1016/j.fct.2011.12.001] [PMID: 22178225]
[21]
Méité S, Bahi C, Yéo D, Datté JY, Djaman JA, N’guessan DJ. Laxative activities of Mareya micrantha (Benth.) Müll. Arg. (Euphorbiaceae) leaf aqueous extract in rats. BMC Complement Altern Med 2010; 10: 7.
[http://dx.doi.org/10.1186/1472-6882-10-7] [PMID: 20158903]
[22]
Wintola OA, Sunmonu TO, Afolayan AJ. The effect of Aloe ferox Mill. in the treatment of loperamide-induced constipation in Wistar rats. BMC Gastroenterol 2010; 10: 95.
[http://dx.doi.org/10.1186/1471-230X-10-95] [PMID: 20723249]
[23]
Bustos D, Ogawa K, Pons S, Soriano E, Bandi JC, Bustos Fernández L. Effect of loperamide and bisacodyl on intestinal transit time, fecal weight and short chain fatty acid excretion in the rat. Acta Gastroenterol Latinoam 1991; 21(1): 3-9.
[PMID: 1811403]
[24]
Yang ZH, Yu HJ, Pan A, et al. Cellular mechanisms underlying the laxative effect of flavonol naringenin on rat constipation model. PLoS One 2008; 3(10): e3348.
[http://dx.doi.org/10.1371/journal.pone.0003348] [PMID: 18833323]
[25]
Kim JE, Park JW, Kang MJ, et al. Anti-inflammatory response and muscarinic cholinergic regulation during the laxative effect of Asparagus cochinchinensis in loperamide-induced constipation of SD rats. Int J Mol Sci 2019; 20(4): 946.
[http://dx.doi.org/10.3390/ijms20040946] [PMID: 30795644]
[26]
Kim JE, Park JW, Kang MJ, et al. Laxative effect of Spicatoside A by cholinergic regulation of enteric nerve in loperamide-induced constipation. ICR Mice Model Molecules 2019; 24(5): 896.
[http://dx.doi.org/10.3390/molecules24050896] [PMID: 30836659]
[27]
Kim JE, Song BR, Yun WB, et al. Correlation between laxative effects of uridine and suppression of ER stress in loperamide induced constipated SD rats. Lab Anim Res 2017; 33(4): 298-307.
[http://dx.doi.org/10.5625/lar.2017.33.4.298] [PMID: 29399027]
[28]
Kim JE, Go J, Sung JE, et al. Laxative effects of Liriope platyphylla are tightly correlated with suppression of endoplasmic reticulum stress in loperamide-induced constipation of SD rats. Lab Anim Res 2016; 32(1): 16-23.
[http://dx.doi.org/10.5625/lar.2016.32.1.16] [PMID: 27051439]
[29]
Kim JE, Lee YJ, Kwak MH, Ko J, Hong JT, Hwang DY. Aqueous extracts of Liriope platyphylla induced significant laxative effects on loperamide-induced constipation of SD rats. BMC Complement Altern Med 2013; 13: 333.
[http://dx.doi.org/10.1186/1472-6882-13-333] [PMID: 24274470]
[30]
Kim JE, Go J, Sung JE, et al. Uridine stimulate laxative effect in the loperamide-induced constipation of SD rats through regulation of the mAChRs signaling pathway and mucin secretion. BMC Gastroenterol 2017; 17(1): 21.
[http://dx.doi.org/10.1186/s12876-017-0576-y] [PMID: 28122499]
[31]
Park JW, Kim JE, Kang MJ, et al. Anti-oxidant activity of gallotannin-enriched extract of galla rhois can associate with the protection of the cognitive impairment through the regulation of BDNF signaling pathway and neuronal cell function in the scopolamine-treated ICR mice. Antioxidants 2019; 8(10): 450.
[http://dx.doi.org/10.3390/antiox8100450] [PMID: 31623364]
[32]
Sacks SH, Zhou W. The role of complement in the early immune response to transplantation. Nat Rev Immunol 2012; 12(6): 431-42.
[http://dx.doi.org/10.1038/nri3225] [PMID: 22627861]
[33]
Schmudde I, Laumonnier Y, Köhl J. Anaphylatoxins coordinate innate and adaptive immune responses in allergic asthma. Semin Immunol 2013; 25(1): 2-11.
[http://dx.doi.org/10.1016/j.smim.2013.04.009] [PMID: 23694705]
[34]
Hanania NA, Cazzola M. Bronchodilators: Beta2-Agonists and Anticholinergics. Philadelphia, PA, USA: Elsevier Inc 2008.
[35]
Rajagopal S, Shenoy SK. GPCR desensitization: Acute and prolonged phases. Cell Signal 2018; 41: 9-16.
[http://dx.doi.org/10.1016/j.cellsig.2017.01.024] [PMID: 28137506]
[36]
Uotani S, Bjørbaek C, Tornøe J, Flier JS. Functional properties of leptin receptor isoforms: internalization and degradation of leptin and ligand-induced receptor downregulation. Diabetes 1999; 48(2): 279-86.
[http://dx.doi.org/10.2337/diabetes.48.2.279] [PMID: 10334302]
[37]
Ronnett GV, Knutson VP, Lane MD. Insulin-induced down-regulation of insulin receptors in 3T3-L1 adipocytes. Altered rate of receptor inactivation. J Biol Chem 1982; 257(8): 4285-91.
[http://dx.doi.org/10.1016/S0021-9258(18)34719-7] [PMID: 7040381]
[38]
Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012; 4(9): a011189.
[http://dx.doi.org/10.1101/cshperspect.a011189] [PMID: 22952397]
[39]
Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997; 7(4): 261-9.
[http://dx.doi.org/10.1016/S0960-9822(06)00122-9] [PMID: 9094314]
[40]
Kim JE, Lee MR, Park JJ, et al. Quercetin promotes gastrointestinal motility and mucin secretion in loperamide-induced constipation of SD rats through regulation of the mAChRs downstream signal. Pharm Biol 2018; 56(1): 309-17.
[http://dx.doi.org/10.1080/13880209.2018.1474932] [PMID: 29952685]
[41]
Yang Y, Choi PP, Smith WW, et al. Exendin-4 reduces food intake via the PI3K/AKT signaling pathway in the hypothalamus. Sci Rep 2017; 7(1): 6936.
[http://dx.doi.org/10.1038/s41598-017-06951-0] [PMID: 28761132]
[42]
Ju WJ, Zhao ZK, Chen SL, et al. Buzhongyiqi decoction protects against loperamide-induced constipation by regulating the arachidonic acid pathway in rats. Front Pharmacol 2020; 11: 423.
[http://dx.doi.org/10.3389/fphar.2020.00423] [PMID: 32317976]
[43]
Ballard J, Shiner M. Evidence of cytotoxicity in ulcerative colitis from immunofluorescent staining of the rectal mucosa. Lancet 1974; 1(7865): 1014-7.
[http://dx.doi.org/10.1016/S0140-6736(74)90416-4] [PMID: 4133699]
[44]
Hodgson HJF, Potter BJ, Jewell DP. C3 metabolism in ulcerative colitis and Crohn’s disease. Clin Exp Immunol 1977; 28(3): 490-5.
[PMID: 891024]
[45]
Teiberg P, Gjone E. Humoral immune system activity in inflammatory bowel disease Stand J Gastroenterol 1975; 7545-9.
[46]
Moon MR, Parikh AA, Pritts TA, et al Interleukin-1beta induces complement component C3 and IL-6 production at the basolateral and apical membranes in a human intestinal epithelial cell line Shock 2000; 13(5): 374-8.
[http://dx.doi.org/10.1097/00024382-200005000-00005] [PMID: 10807012]

Rights & Permissions Print Cite
Article Metrics
61
1
© 2024 Bentham Science Publishers | Privacy Policy